The theme of this thread appears to demonstrate the lack of understanding amongst the posters here of what clinical conditions you might use Ferriscan for, something I pointed out here more than a year ago. Iron overload syndromes are not common. Haemochromatosis is one, and in that condition you are not interested in the amount of iron but the amount of fibrosis, which no MRI technique can currently quantify. Transfusion-dependent conditions are another, but quantifying liver iron in these is of relatively infrequent importance. Ferriscan is not a 'non-invasive liver biopsy' - it can only quantify iron and it cannot look at inflammation or fibrosis which are usually more important pieces of information. So it is, and will remain, a boutique test, only used by specialists in tertiary care centres, and certainly not by your local GP. Doctors are not stupid - they use tests that provide useful results, and don't use tests marketed to them if it's not going to help their patients. The problem with this company for shareholders is that it provides a nice earner for staff, but does not generate enough income to provide dividends for shareholders. That's why it's not an attractive buy and languishes even lower than the last time I commented here.
RHT Price at posting:
2.5¢ Sentiment: None Disclosure: Not Held
